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Abstract 
Background: We investigated the effect of longitudinal status change in metabolic syndrome (MetS) assessed by 
two different criteria on new onset of type 2 diabetes (NODM) in a Japanese population.
Methods: The participants were 827 non-diabetic citizens who had undergone medical examinations in 1994 and 
2003 or 2004. We used two different criteria of MetS: the interim criteria by 6 institutions (MetS-INT) and Japanese 
criteria (MetS-JP). According to the interim criteria, individuals defined as having MetS have any three of the following 
five components of MetS: obesity, hyperglycemia, high blood pressure, hypertriglyceridemia and low HDL cholester-
olemia. According to the Japanese criteria, individuals defined as having MetS must have abdominal obesity plus any 
two of the following three factors; hyperglycemia, high blood pressure and dyslipidemia (hypertriglyceridemia and/
or low HDL-cholesterolemia). According to the status change in MetS, participants were divided into four groups: a 
non-MetS to non-MetS group, a non-MetS to MetS group, a MetS to non-MetS group and a MetS to MetS group. We 
calculated odds ratios of these four groups for NODM.
Results: NODM occurred in 65 participants. The odds ratios for NODM were 4.86, 4.97 and 7.50 in the non-MetS-INT 
to MetS-INT group, MetS-INT to non-MetS-INT group and MetS-INT to MetS-INT group, respectively. On the other 
hand, the odds ratios were 4.28 and 15.55 in the non-MetS-JP to MetS-JP group and MetS-JP to MetS-JP group, 
respectively. After adjustment for high fasting plasma glucose at baseline, magnitude of the odds ratio of MetS to 
MetS group was larger in the Japanese criteria group than in the interim criteria group.
Conclusions: Determining the status of MetS routinely and paying attention to status change in MetS may be 
important for prevention of type 2 diabetes. MetS defined by the criteria which includes obesity as a prerequisite 
component may be a stronger risk for type 2 diabetes than MetS defined by the criteria which includes obesity as one 
of components.
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Background
Metabolic syndrome (MetS) is one of the useful predic-
tors for future occurrence of type 2 diabetes as well as 
cardiovascular disease [1–8]. However, there are different 
criteria for diagnosis of MetS, which cause some confu-
sion because there are some differences in prevalence of 
MetS by using various criteria. A joint interim statement 
has been issued by the International Diabetes Federa-
tion (IDF) Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute (NHLBI); 
American Heart Association (AHA); World Heart Fed-
eration; International Atherosclerosis Society; and Inter-
national Association for the Study of Obesity. According 
to the statement, abdominal obesity should not be a pre-
requisite for diagnosis, but it is 1 of 5 criteria, 3 of which 
constitute a diagnosis of metabolic syndrome [9]. On 
the other hand, according to the Japanese criteria [10], 
as in the previous IDF criteria [11], abdominal obesity is 
a prerequisite for diagnosis of MetS because there is an 
emphasis in the Japanese criteria that abdominal obesity 
is a background for risk accumulation in the pathologi-
cal mechanism of metabolic syndrome. Because obesity, 
especially abdominal obesity, is considered to be a strong 
risk factor for new onset of type 2 diabetes (NODM) [12, 
13], there may be some difference in the predictive power 
for NODM if abdominal obesity is prerequisite or not.
To prevent occurrence of type 2 diabetes and car-
diovascular disease, life style intervention is important 
for individuals with MetS [14, 15]. A recent large-scale 
observational study showed that life style intervention 
in individuals with MetS was related with 25  % risk-
reduction of type 2 diabetes and 50  % risk-reduction of 
cardiovascular disease [15]. During life style interven-
tion period, repeated assessment of whether they satisfy 
MetS criteria or not is important for determining the 
effectiveness of the life style intervention [16]. Although 
many studies have shown that MetS at baseline is a use-
ful predictor of the future occurrence of type 2 diabetes, 
the impact of longitudinal status change in MetS on new 
onset of type 2 diabetes has not been determined.
In this study, we therefore investigated the effect of lon-
gitudinal status change in MetS defined by two different 
criteria on NODM in a general Japanese population.
Methods
Participants
We have been conducting a cohort study called “The 
Tanno–Sobetsu study” since 1977. Annual health check-
ups, including standard blood and urine tests and an 
electrocardiogram, have been conducted for all residents 
aged 30 years or more of Tanno town and Sobetsu town. 
The two towns are in rural areas of Hokkaido, the north-
ernmost island of Japan, and the major industry in both 
towns is agriculture. Most of participants in this cohort 
are middle-aged and elderly people and their life style, 
prevalence of obesity, blood pressure, and blood glu-
cose and serum lipid levels are similar to the results of 
a national survey in Japan. Therefore, this cohort is con-
sidered to represent Japanese middle-aged and elderly 
population.
In this study, of 1908 residents who were aged 30 years 
or older when they received medical examinations in the 
two towns in 1994, 938 also underwent medical exami-
nations in 2003 or 2004. From the 938 residents, we 
excluded 70 individuals without data for MetS compo-
nents and 41 individuals who had type 2 diabetes in 1994 
(individuals with fasting plasma glucose (FPG) ≥126 mg/
dl [17] and/or individuals on medication for type 2 diabe-
tes). The remaining 827 individuals were participants in 
this study.
This study was approved by the Ethics Committee of 
Sapporo Medical University and we received written 
informed consent from all participants.
Measurement items
Waist circumference, body mass index (BMI), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), 
fasting plasma glucose (FPG), total cholesterol (T.chol), 
triglycerides (TG), and HDL cholesterol (HDL-C) were 
measured in each participant. After 5 min of rest, blood 
pressure levels (SBP and DBP) were measured twice in a 
sitting position and average values were used for analysis. 
FPG level, T.chol level, TG level and HDL-C level were 
measured by the hexokinase method, cholesterol oxi-
dase method, enzymatic method and the direct method, 
respectively.
Criteria of metabolic syndrome
Participants with MetS were determined according to 
two different criteria: the interim criteria by 6 institutions 
[9] and the Japanese criteria [10]. Differences among the 
two criteria are simply described below.
According to the interim criteria, individuals defined 
as having MetS (MetS-INT) have any three of the fol-
lowing five components of MetS: elevated waist cir-
cumference (waist circumference ≥90  cm for men and 
≥80 cm for women; Asian criteria), hypertriglyceridemia 
(TG ≥150 mg/dl and/or on drug treatment for elevated 
triglycerides), low HDL cholesterolemia (HDL-C <40 mg/
dl for men and <50 mg/ml for women), high blood pres-
sure (SBP ≥130 mmHg and/or DBP ≥85 mmHg and/or 
treatment for previously diagnosed hypertension) and 
high FPG (FPG ≥100 mg/dl).
According to the Japanese criteria, individuals defined 
as having MetS (MetS-JP) must have abdominal obe-
sity (waist circumference ≥85  cm for men and ≥90  cm 
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for women) plus any two of the following three factors: 
dyslipidemia (TG ≥150 mg/dl and/or HDL-C <40 mg/dl 
and/or specific treatment for these), high blood pressure 
(SBP ≥130 mmHg and/or DBP ≥85 mmHg and/or treat-
ment for previously diagnosed hypertension) and high 
FPG (FPG ≥110 mg/dl) (Table 1).
Statistical analysis
According to the status change in MetS between 1994 
and 2003 or 2004, participants were divided by using 
each of the criteria separately into four groups: a non-
MetS to non-MetS group, a non-MetS to MetS group, a 
MetS to non-MetS group and a MetS to MetS group. We 
calculated the odds ratio of MetS at baseline and the odds 
ratios of the above four groups for NODM (individuals 
with FPG ≥126  mg/dl [17] or individuals who were on 
medication for type 2 diabetes on the basis of the 2003 or 
2004 medical examination data).
IBM SPSS Statistics ver.22 was used for statisti-
cal analysis. The significance level in all analyses was 
set at p  <  0.05. All numerical values are expressed as 
mean  ±  SD or medians and ranges. Student’s t test, 
analysis of variance (ANOVA), the Kruskal–Wallis test, 
Dunnett’s test and Fisher’s exact test with Bonferroni cor-
rection were used for examination of intergroup differ-
ences compared with the non-MetS to non-MetS group 
and for frequency comparison. Multiple logistic regres-
sion analysis was used to estimate the odds ratios of 
NODM. Age, sex were selected as confounding factors in 
model 1. Then high FPG (FPG ≥100 mg/dl for MetS-INT 
and ≥110 mg/dl for MetS-JP) at baseline was additionally 
included in the Model 2 (Model 2).
Results
Table 2 shows the baseline characteristics of participants 
by gender. Mean age, waist circumference, TG, FPG 
and percentages of participants with abdominal obesity 
assessed by the Japanese criteria, smoking, IFG, high TG, 
low HDL-C assessed by the Japanese criteria and MetS-
JP were significantly higher in men than in women. SBP, 
T.chol, HDL-C and percentage of participants with low 
HDL-C assessed by the interim criteria were significantly 
higher in women than in men. There were no significant 
differences in BMI, DBP, percentages of participants with 
a family history of type 2 diabetes, abdominal obesity 
assessed by the Asian criteria, high blood pressure and 
MetS-INT between men and women.
Figure 1 shows the follow-up results in this study. Dur-
ing the follow-up period, NODM occurred in 65 partici-
pants. When using the MetS criteria by 6 institutions, 
there were 666 individuals in the non-MetS-INT group 
and 161 in the MetS-INT group at baseline. Of the 666 
individuals in the non-MetS-INT group, 487 remained 
in the non-MetS-INT category in 2003 or 2004, and the 
remaining 173 individuals changed to the MetS-INT 
category in 2003 or 2004. One hundred fifteen of the 
161 individuals in the MetS-INT group remained in the 
MetS-INT category in 2003 or 2004, and the remaining 
46 individuals changed to the non-MetS-INT category 
(Fig.  1a). When using the Japanese MetS criteria, there 
were 760 individuals in the non-MetS-JP group and 67 in 
the MetS-JP group at baseline. Of the 760 individuals in 
the non-MetS-JP group, 644 remained in the non-MetS-
JP category in 2003 or 2004, and the remaining 116 indi-
viduals changed to the MetS-JP category in 2003 or 2004. 
Thirty-four of the 67 individuals in the MetS-JP group 
remained in the MetS-JP category in 2003 or 2004, and 
the remaining 33 individuals changed to the non-MetS-
JP category (Fig. 1b).
Table  3 shows the baseline characteristics among 
status-change categories defined by the interim crite-
ria of MetS. BMI, waist circumference, SBP, DBP, FPG 
and percentages of participants with abdominal obe-
sity, high BP, high FPG, high TG and low HDL-C were 
Table 1 Comparisons of international criteria of metabolic syndrome and Japanese criteria of metabolic syndrome
SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, HDL-C HDL cholesterol, FPG fasting plasma glucose
International criteria Japanese criteria
Absolutely required None Central obesity (waist circumference ≥85 cm for men 
and ≥90 cm for women
Criteria Any three of the five criteria below Obesity, plus two of the three criteria below
Obesity Elevated waist circumference (waist circumference ≥90 cm for 
men and ≥80 cm for women; Asian criteria)
(Central obesity already required)
High blood pressure SBP ≥130 mmHg and/or DBP ≥85 mmHg and/or treatment 
for previously diagnosed hypertension
SBP ≥130 mmHg and/or DBP ≥85 mmHg and/or treatment for 
previously diagnosed hypertension
Dyslipidemia TG ≥150 mg/dl and/or on drug treatment for elevated  
triglycerides
TG ≥150 mg/dl and/or HDL-C <40 mg/dl for both gender and/
or specific treatment for these
HDL-C <40 mg/dl for men and <50 mg/dl for women
Hyperglycemia FPG ≥100 mg/dl FPG ≥110 mg/dl
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significantly higher in the non-MetS-INT to MetS-INT 
group, MetS-INT to non-MetS-INT group and MetS-
INT to MetS-INT group than in the non-MetS-INT to 
non-MetS-INT group (reference group). Mean age and 
T.chol were higher in the non-MetS-INT to MetS-INT 
group and MetS-INT to MetS-INT group than in the 
reference group. The percentage of men was lower in the 
non-MetS-INT to MetS-INT group and was higher in 
the MetS-INT to non-MetS-INT group than in the ref-
erence group. The percentage of participants with a fam-
ily history of type 2 diabetes was higher in the MetS-INT 
to MetS-INT group than in the reference group. HDL-C 
was lower in the above three groups than in the reference 
group.
Table  4 shows the baseline characteristics among sta-
tus-change categories defined by the Japanese criteria of 
MetS. BMI, waist circumference, SBP, DBP, FPG, per-
centage of men, and percentages of participants with 
abdominal obesity, high BP, high FPG, high TG and low 
HDL-C were significantly higher in the non-MetS-JP 
to MetS-JP group, MetS-JP to non-MetS-JP group and 
MetS-JP to MetS-JP group than in the non-MetS-JP to 
non-MetS-JP group (reference group). Mean age was 
higher in the non-MetS-JP to MetS-JP group and MetS-
JP to non-MetS-JP group than in the reference group. 
T.chol was higher in the non-MetS-INT to MetS-INT 
group than in the reference group. The percentage of par-
ticipants with a family history of type 2 diabetes tended 
to be higher in the MetS-JP to MetS-JP group than in the 
reference group, but the difference was not statistically 
significant. HDL-C was lower in the above three groups 
than in the reference group.
Table  5 shows the results of multiple logistic regres-
sion analysis. The odds ratios for NODM in individuals 
with MetS-INT and individuals with MetS-JP at baseline 
adjusted for age and sex were 3.46 and 5.15, respectively 
(Model 1). When we additionally adjusted for high FPG 
at baseline (Model 2), MetS-INT lost its significance, but 
the odds ratio of MetS-JP was 3.45 and still retained its 
statistical significance. As for status change of MetS, the 
odds ratios for NODM were 4.86, 4.97 and 7.50 in the 
non-MetS-INT to MetS-INT group, MetS-INT to non-
MetS-INT group and MetS-INT to MetS-INT group 
(Model 1), respectively. However, in Model 2, only the 
odds ratio of non-MetS-INT to MetS-INT group and 
MetS-INT to MetS-INT group retained its significance. 
On the other hand, the odds ratios were 4.28 and 15.55 
in the non-MetS-JP to MetS-JP group and MetS-JP to 
MetS-JP group, respectively (Model 1), and both of them 
still retained their significance after adjustment for high 
Table 2 Baseline characteristics of subjects by sex, 1994
Abdominal obesity by Asian criteria: 90 cm for men and 80 cm for women; Abdominal obesity by Japanese criteria: 85 cm for men and 90 cm for women; MetS-INT 
metabolic syndrome assessed by the interim criteria by 6 institutions, MetS-JP metabolic syndrome assessed by the Japanese criteria
Men Women p
n 347 480
Mean age (years) 59.6 ± 9.0 58.3 ± 8.5 0.034
Family history of type 2 diabetes (%) 9.2 11.3 0.387
Body mass index (kg/m2) 23.5 ± 3.1 23.5 ± 2.8 0.784
Waist circumference (cm) 83.2 ± 9.2 75.2 ± 8.1 <0.0001
Abdominal obesity (Asian criteria) (%) 23.3 29.0 0.079
Abdominal obesity (Japanese criteria) (%) 42.1 5.6 <0.0001
Systolic blood pressure (mmHg) 131.3 ± 17.3 134.1 ± 19.2 0.028
Diastolic blood pressure (mmHg) 78.4 ± 9.1 77.7 ± 9.8 0.320
Total cholesterol (mg/dl) 183.8 ± 29.7 199.6 ± 31.6 <0.0001
Triglycerides (mg/dl) 144.2 ± 106.7 117.7 ± 76.6 <0.0001
HDL-C (mg/dl) 53.2 ± 13.5 57.7 ± 13.5 <0.0001
Fasting plasma glucose (mg/dl) 94.8 ± 10.4 93.0 ± 8.8 0.008
Smoking (%) 69.7 7.3 <0.0001
High blood pressure (%) 56.8 58.8 0.617
Impaired fasting glucose (%) 27.4 19.6 0.009
High triglycerides (≥150 mg/dl) (%) 30.3 17.1 <0.0001
Low HDL-C (INT) (<40 mg/dl for men and <50 mg/dl for women) (%) 15.3 27.1 <0.0001
Low HDL-C (JP) (<40 mg/dl for men and women) (%) 15.3 8.8 0.004
MetS-INT (%) 20.7 18.5 0.477
MetS-JP (%) 17.3 1.5 <0.0001
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FPG at baseline (Model 2). Status change of MetS-JP to 
non-MetS-JP was not selected as a significant risk for 
NODM. Magnitude of the odds ratio of MetS to MetS 
group was larger in the Japanese criteria group than in 
the interim criteria group.
Discussion
The main findings of this study are [1] MetS assessed 
by both of the criteria at baseline were significant pre-
dictors of NODM and MetS-JP only retained its sig-
nificance after adjustment for high FPG at baseline, [2] 
status change of non-MetS to MetS was a significant risk 
for NODM, and maintenance of status of MetS was the 
strongest risk for NODM, and [3] magnitude of the odds 
ratio of MetS to MetS group was larger in the Japanese 
criteria group than in the interim criteria group.
The results of this study showed that MetS-JP still 
maintained its significance after adjustment for high FPG 
at baseline. According to the Japanese criteria of MetS 
[10], the definition of MetS must include abdominal 
obesity as in the previous International Diabetes Federa-
tion (IDF) definition [11], because the accumulation of 
visceral fat in individuals with MetS is considered to be 
important for the mechanism underlying the accumula-
tion of risk factors for cardiovascular disease. Abdominal 
obesity, which is one of the background factors of insu-
lin resistance, may lead to the accumulation of coronary 
risk factors and to the development of type 2 diabetes. 
Ford et al. [18] reported that MetS was a risk factor for 
future occurrence of type 2 diabetes in Europeans and 
that abdominal obesity and impaired fasting glucose 
(IFG) were the two strongest predictors of incident dia-
betes. Marott et al. [19] also reported that waist circum-
ference and glucose level were strongly associated with 
occurrence of type 2 diabetes. Mukai et al. reported that 
when using the criteria of metabolic syndrome reported 
by AHA/NHLBI [20], metabolic syndrome that did not 
include the IFG component was also a significant risk 
factor for the development of type 2 diabetes and that 
the coexistence of metabolic syndrome and IFG greatly 
increased the risk of future type 2 diabetes in the general 
Japanese population [7]. Therefore, the Japanese criteria 
of MetS, which can efficiently identify individuals with 
the coexistence of abdominal obesity and high FPG, may 
be a more useful predictor for NODM than the interim 
criteria.
In this study, new change to MetS was a strong risk 
for the development of type 2 diabetes and maintenance 
of the status of MetS was the strongest risk factor for 
NODM when using both criteria. Status change of MetS 
may be an indication of the duration of MetS, and the 
results of this study may mean that the longer the dura-
tion of MetS is, the higher is the risk for development of 
type 2 diabetes. After adjustment for high FPG at base-
line, magnitude of odds ratio of MetS to MetS group was 
larger in the Japanese criteria group than in the interim 
criteria group. One of the reasons why status change 
of MetS-JP was a stronger risk for type 2 diabetes than 
status change of MetS-INT may be the issue of whether 
abdominal obesity is prerequisite or not. Because abdom-
inal obesity plays an important role in the status change 
of MetS-JP, status change of MetS-JP to MetS-JP means 
a continuation of abdominal obesity. On the other hand, 
status change of MetS-INT to MetS-INT does not 
always mean continuation of abdominal obesity because 
abdominal obesity is not a prerequisite for diagnosis in 
the criteria. Another reason may be that there are several 
differences in the cut-off points of components of MetS 
between the criteria. Differences in the cut-off points of 
waist circumference, high FPG level and HDL-C level 
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Fig. 1 a Shows number of individuals newly defined as having type 
2 diabetes in four status-change groups when using the interim 
criteria of MetS. b Shows number of individuals newly defined as 
having type 2 diabetes in four status-change groups when using 
the Japanese criteria of MetS. MetS-INT metabolic syndrome defined 
by the interim criteria, MetS-JP metabolic syndrome defined by the 
Japanese criteria follow-up results by different criteria of MetS
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of men and individuals with higher levels of FPG in the 
MetS group. When using the Japanese criteria, preva-
lence of MetS-JP was lower than that of MetS-INT, but 
percentages of men and individuals with IFG, which is 
considered to be a risk factor for NODM, were higher in 
the MetS-JP group than in the MetS-INT group. These 
may also explain why the results of status change of MetS 
to non-MetS were different between MetS-INT and 
MetS-JP.
One of clinical implications of this study is that 
the results may be useful in education for commu-
nity dwellers with MetS by public health workers. The 
impact of maintained status of MetS on NODM may 
motivate community dwellers with MetS to change 
their life styles. It is known that life style intervention 
for individuals with impaired glucose tolerance (IGT) 
or MetS can prevent type 2 diabetes [21–25]. In the 
present observational study, we could not find an effect 
of status change in MetS to non-MetS on prevention of 
NODM. Further interventional studies are needed to 
assess the effect of improvement in the status of MetS 
on NODM.
There are some limitations in this study. First, we could 
not assess the gender difference in the effect of status 
change of MetS on NODM because our sample size was 
relatively small. Further large-scale studies are needed to 
evaluate the gender difference. Second, there may be a 
self-selection bias because we included participants who 
received the health checkups in both 1994 and 2003 or 
2004. Therefore, we may have underestimated the impact 
Table 3 Baseline characteristics among status-change categories defined by international criteria of metabolic syndrome
Asian criteria of abdominal obesity, waist circumference ≥90 cm for men and ≥ 80 cm for women
High blood pressure, systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or medication for hypertension
High fasting plasma glucose, fasting plasma glucose ≥100 mg/dl; high triglycerides, triglycerides ≥150 mg/dl; Low HDL-C, HDL cholesterol <40 mg/dl for men 
and <50 mg/dl for women
Continuous variables are expressed as means ± SD or medians (range)
* p < 0.05 vs. Non-MetS to Non-MetS group using Dunnet’s test
# p < 0.05 vs. Non-MetS to Non-MetS group using Bonferroni correction
a Analysis of variance (ANOVA)











n 487 179 46 115
Mean age (years) 57.8 ± 9.1 59.8 ± 7.8* 60.8 ± 7.5 62.8 ± 7.8* <0.001a
Men (%) 44.8 28.4# 65.2# 46.5 <0.001b
Family history of type 2  
diabetes (%)
5.5 6.3 2.2 16.3# 0.005b
Body mass index (kg/m2) 22.5 ± 2.5 24.3 ± 2.7* 25.7 ± 2.1* 27.1 ± 2.4* <0.001a
Waist circumference (cm) 75.7 ± 8.3 79.8 ± 8.5* 91.7 ± 5.2* 89.7 ± 7.5* <0.001a
Systolic blood pressure  
(mmHg)
128.8 ± 17.4 135.4 ± 17.5* 145.2 ± 16.3* 150.4 ± 16.1* <0.001a
Diastolic blood pressure 
(mmHg)
76.3 ± 9.1 79.3 ± 9.3* 85.7 ± 9.3* 83.3 ± 9.0* <0.001a
Total cholesterol (mg/dl) 189.9 ± 30.7 196.6 ± 32.6* 194.8 ± 32.9 203.6 ± 33.1* 0.001a
Triglycerides (mg/dl) 93 (42–635) 125 (45–554) 141 (52–506) 157 (47–1127) <0.001§
HDL-C (mg/dl) 59.3 ± 13.2 51.5 ± 13.4* 50.6 ± 10.2* 46.7 ± 10.7* <0.001a
Fasting plasma glucose (mg/dl) 91.7 ± 8.9 95.1 ± 8.8* 100.6 ± 8.8* 101.6 ± 10.5* <0.001a
Smoking never smoker (%) 65.3 73.6 50.0 65.1 0.001b
Ex-smoker (%) 8.6 5.8 21.7 17.4
Current smoker (%) 26.1 20.7 28.3 17.4
Abdominal obesity (Asian 
criteria) (%)
12.3 27.4# 60.9# 87.2# <0.001b
High blood pressure (%) 45.4 64.9# 91.3# 94.2# <0.001b
High fasting plasma  
glucose (%)
13.3 23.1# 65.2# 53.5# <0.001b
High triglycerides (%) 10.7 25.5# 65.2# 60.5# <0.001b
Low HDL-C (%) 10.5 30.3# 47.8# 54.7# <0.001b
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of status change of MetS on NODM. Third, we could not 
assess the components of both criteria of MetS for which 
changes are important to predict NODM and we could 
not assess the appropriate cut-off points of components 
of both criteria because of the small sample size. Further 
studies are needed to examine these issues. Forth, we 
may underestimate number of new onset type 2 diabetes 
because we did not conduct 75 g oral glucose tolerance 
test to define new onset of type 2 diabetes. Fifth, we could 
not consider effects of several confounding factors such 
as antihypertensive agents, family history of type 2 dia-
betes and body mass index in multiple logistic regression 
models because of small sample size. Further large-scale 
studies are needed to consider effects of several con-
founding factors other than fasting plasma glucose level 
at a time.
Conclusion
In conclusion, the results of this study show that not only 
MetS at baseline but also longitudinal status change in 
MetS are useful for assessing the risk of future develop-
ment of type 2 diabetes. Our results suggest that rou-
tinely determining the status change of MetS and paying 
attention to status change of MetS may be important 
for prevention of the future occurrence of type 2 diabe-
tes. Status change of MetS defined by the criteria which 
Table 4 Baseline characteristics among status-change categories defined by Japanese criteria of MetS
Japanese criteria of abdominal obesity, waist circumference ≥85 cm for men and ≥90 cm for women
High blood pressure, systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or medication for hypertension
High fasting plasma glucose, fasting plasma glucose ≥110 mg/dl; High triglycerides, triglycerides ≥150 mg/dl; Low HDL-C, HDL cholesterol <40 mg/dl for both men 
and women
Continuous variables are expressed as means ± SD or medians (range)
* p < 0.05 vs. Non-MetS to Non-MetS group using Dunnet’s test
# p < 0.05 vs. Non-MetS toNon-MetS group using Bonferroni correction
a Analysis of variance (ANOVA)
b Fisher’s exact test
c Kruskal–Wallis test
Non-MetS-JP to non-Met-JP Non-MetS-JP to MetS-JP MetS-JP to Non-MetS-JP MetS-JP to MetS-JP p
n 644 116 33 34
Mean age (years) 58.2 ± 8.9 60.9 ± 7.1* 62.2 ± 7.4* 61.2 ± 10.3 0.001a
Men (%) 34.9 53.5# 93.9# 85.3# <0.001b
Family history of type 2 
diabetes (%)
6.2 6.9 3.0 17.6 0.087b
Body mass index (kg/m2) 22.9 ± 2.7 25.1 ± 2.8* 25.0 ± 1.9* 27.2 ± 3.3* <0.001a
Waist circumference (cm) 76.1 ± 8.3 84.2 ± 7.4* 89.9 ± 4.3* 94.2 ± 6.5* <0.001a
Systolic blood pressure 
(mmHg)
130.9 ± 18.2 137.1 ± 17.6* 144.9 ± 15.5* 146.3 ± 16.9* <0.001a
Diastolic blood pressure 
(mmHg)
77.0 ± 9.5 79.8 ± 8.5* 82.5 ± 7.4* 86.0 ± 8.5* <0.001a
Total cholesterol (mg/dl) 191.7 ± 31.4 200.3 ± 34.3* 192.7 ± 27.8 194.0 ± 31.0 0.064a
Triglycerides (mg/dl) 98.5 (42–635) 129.5 (51–1109) 186 (47–506) 181.5 (62–1127) <0.001c
HDL-C (mg/dl) 57.8 ± 13.3 51.4 ± 13.0* 46.0 ± 10.9* 43.6 ± 11.4* <0.001a
Fasting plasma glucose  
(mg/dl)
92.5 ± 9.0 96.0 ± 9.2* 100.2 ± 10.5* 103.0 ± 11.0* <0.001a
Smoking never smoker (%) 71.9 53.5 39.4 35.3 <0.001b
Ex-smoker (%) 7.0 14.7 24.2 26.5
Current smoker (%) 21.1 31.9 36.4 38.2
Abdominal obesity (Japanese 
criteria) (%)
10.3 34.5# 100.0# 100.0# <0.001b
High blood pressure (%) 52.3 67.2# 93.9# 97.1# <0.001b
High fasting plasma glucose 
(%)
4.0 7.8# 30.3# 38.2# <0.001b
High triglycerides (%) 15.2 32.8# 81.8# 70.6# <0.001b
Low HDL-C (%) 7.8 17.2# 30.3# 44.1# <0.001b
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includes obesity as a prerequisite component may be a 
stronger risk for type 2 diabetes than MetS defined by the 
criteria which includes obesity as one of components.
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